Premium
DIAGNOSIS OF PULMONARY ASPERGILLOSIS UTILIZING PROTEOMICS TECHNOLOGY
Author(s) -
Martin Matthew,
Furamga Wieslaw,
Mikhailov Valery
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.47.9
Subject(s) - galactomannan , pulmonary aspergillosis , aspergillosis , pathology , aspergillus , lung , medicine , biology , microbiology and biotechnology , immunology
Background: Lack of characteristic symptoms and adequate testing for pulmonary aspergillosis in immunocompromised host delays therapy, resulting in 80% mortality rate. Diagnosis requires biopsy with visualization of fungal hyphae and positive culture. It takes several days with 50% of false‐negative results. The non‐invasive assays (PCR, galactomannan, beta‐glucan) are impeded by false‐positive and false‐negative results. To find a better marker for pulmonary aspergillosis, we performed serum protein profiling on infected and non‐infected guinea pigs. Methods: Using SELDI‐TOF, serum was tested on CM10, Q10, H50, IMAC microchips and protein profile was obtained from Aspergillus infected and non‐infected animals terminated 1h and 3, 5, 7 days after inoculation. Difference in profiling was evaluated by hierarchical clustering and principal component analysis. Results: Two distinctive peaks in infected and one peak in non‐infected animals were identified. Future protein identification and validation as a potential diagnostic marker is warranted. Conclusion: Our study discovered exclusive spectrometric peaks that may contain potential biomarkers for early diagnosis of systemic aspergillosis.